Mobia Medical, Inc.

Mobia Medical, Inc. filed its Q1 2026 10-Q report, showing a substantial increase in revenue to $12.07 million from $5.66 million in the prior year's quarter. However, the company also reported a widening net loss of $17.74 million for the quarter, up from $10.65 million in Q1 2025, driven by increased operating expenses. The company highlights its recent IPO in May 2026, which provided significant proceeds and is expected to fund operations for at least one year, alleviating immediate going concern doubts. Despite revenue growth, the company continues to face risks related to market acceptance, reimbursement, and operational costs.

Mobia Medical, Inc. filed an amended and restated certificate of incorporation and bylaws on May 11, 2026, in connection with the closing of its initial public offering. The amendments include fixing the authorized common stock at 950,000,000 shares and authorizing 50,000,000 shares of undesignated preferred stock. The company also established a classified board of directors, restricted director removal, and eliminated the ability of stockholders to act by written consent. Additionally, the amendments designate specific Delaware and federal courts as exclusive forums for certain legal actions.

Mobia Medical, Inc. filed an S-1/A amendment detailing its initial public offering of 10,000,000 shares of common stock, expected to price between $14.00 and $16.00 per share and trade on Nasdaq under "MOBI". The company also issued $40.0 million in convertible notes in early 2026, which will convert into common stock upon the IPO's closing. Mobia Medical, a commercial-stage medical device company, reported 2025 revenue of $32.0 million, a 104.8% increase year-over-year, with a net loss of $46.5 million.

Mobia Medical, Inc. (MOBI) filed an S-1/A for its initial public offering of common stock, which is expected to trade on the Nasdaq Global Select Market. The company, a commercial-stage medical device firm, offers the FDA-approved Vivistim Paired VNS System for chronic ischemic stroke recovery. Mobia reported significant growth, with 2025 revenue of $32.0 million, a 104.8% increase year-over-year, and over 1,000 Vivistim System implants to date. The company also recently issued $40.0 million in convertible notes that will convert at the IPO.